INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. regarding allegations of securities fraud and unlawful business practices related to the company's performance and disclosures [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Altimmune and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Altimmune securities during the Class Period have until October 6, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [4]. - The company had previously set inflated expectations for the trial results, but the analysis revealed a higher-than-expected placebo response that contributed to the failure [4]. - Following the announcement of the trial results, Altimmune's stock price fell by $4.10 per share, or 53.2%, closing at $3.61 per share [5].